芬妥木单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | IGF-1受体 |
| 臨床資料 | |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 943453-46-1  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6462H9948N1736O2020S54 |
| 摩尔质量 | 146,008.04 g·mol−1 |
芬妥木单抗（INN：Figitumumab；开发代号：CP-751871）是一种针对胰岛素样生长因子1受体的单克隆抗体，[1]已被研究用于治疗多种癌症，例如肾上腺皮质癌[2]和非小细胞肺癌。[3]
这种药物由辉瑞公司开发，但他们于2011年1月停止了该药物的开发并停止了生产。[4]
临床试验
第一个III期试验（针对非小细胞肺癌）因死亡人数过多而于2009年12月暂停，[5]但其他试验仍在继续。[6][7]
参考资料
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology. March 2010, 65 (4): 765–73. PMC 2875253
. PMID 19649631. doi:10.1007/s00280-009-1083-9.
- ^ Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clinical Lung Cancer. July 2009, 10 (4): 273–80. PMID 19632947. doi:10.3816/CLC.2009.n.038.
- ^ Cancer sufferer fears future without 'life-saver' drug. BBC News. July 2014 [2024-01-22]. （原始内容存档于2015-09-25）.
- ^ Krauskopf L. Pfizer ends late-stage lung-cancer study. Reuters. 29 December 2009 [2024-01-22]. （原始内容存档于2010-02-26）.
- ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
- ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
- ^ Breast cancer study aims to speed drugs, cooperation. Reuters. March 2010 [2024-01-22]. （原始内容存档于2010-03-22）.
| |||||||||||||||||||||||||||||||||||||||